Enzo Biochem, Inc.New York, NY United States
Company Description
For Enzo Biochem, antisense is perfectly sensible. The biotech company's Enzo Therapeutics segment develops antisense technology, a kind of gene therapy that switches off disease-causing genes, to fight such illnesses as HIV and Crohn's disease. Its work is funded by its two other segments: Enzo Clinical Labs which provides diagnostic testing services in the New York City area and Enzo Life Sciences which makes reagents used in research by pharmaceutical and biotech companies, as well as academic institutions. Enzo Biochem has collaborative partnerships with academic and research centers such as the
| 527 Madison Ave. | Phone: 212-583-0100 | http://www.enzo.com |
| New York, NY 10022 | 
Map This Company | |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Enzo Biochem, Inc. Rankings
| S&P 600 | Russell 2000 (June 2011) |
Executives
| 20 executives listed for Enzo Biochem, Inc.'s New York, NY location. | ||
| Chairman, CEO, and Secretary | Elazar Rabbani | |
|---|---|---|
| President, CFO, Principal Accounting Officer, Treasurer, and Director | Barry Weiner | |
| VP Business Development; COO, Enzo Life Sciences | AndrewWhiteley | |
Financials
| Company Type | Public - NYSE: ENZ Headquarters |
|---|---|
| Fiscal Year-End | July |
| 2011 Employees | 606 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Enzo Biochem, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
